The Hype Behind Vertex Pharmaceuticals Incorporated (VRTX), Brocade Communications Systems, Inc. (BRCD)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were trading lower by -0.32 percent ($-0.5) at $154.02 a piece in Wednesday’s session. It had closed the previous session at $154.52. VRTX trades with a P/S ratio of 18.24. This is lower than the industry’s 89.99 but higher compared with the wider sector’s 13.12. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 50.22 and a trailing 12-month price-earnings (P/E) multiple of 149.1. Shares of VRTX have uptrended 17.64% in the past three months, while the S&P 500 has moved 11.18% in that time. Vertex Pharmaceuticals Incorporated (VRTX) has a market cap of $38.89 billion and over the last 12 months, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has gone stronger by 88.61%. During the last 52 weeks, the (NASDAQ:VRTX) price has been as high as $167.85 and as low as $71.46. Vertex Pharmaceuticals Incorporated earnings have declined with an annualized rate of -39.4% over the last 5 years.

Vertex Pharmaceuticals Incorporated (Mean Target Price: $180)

The average 1-year price target for Vertex Pharmaceuticals Incorporated (VRTX) — averaging the work of different analysts — reveals a mean PT of $180/share. That’s a potential 16.87 increase relative to where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been trading recently. The current price is seen ranging between $151.65 and $154.64. There are brokerage firms with lower targets than the average, including one setting a price target of $85. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $215.

Vertex Pharmaceuticals Incorporated (VRTX) Consensus Recommendation

The collective rating of 1.8 for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) also leans strongly towards the bullish end of the spectrum. Of the 27 analysts surveyed by Reuters that track VRTX 5 of them rate its stock a hold. The other 22, though not evenly; between analysts who think you should buy Vertex Pharmaceuticals Incorporated versus those who think you should sell it. A 22 analysts rate it as either a buy or a strong buy, while0 believe that investors should either steer clear of VRTX or, if they already own its stock, sell it.

Is Brocade Communications Systems, Inc. (NASDAQ:BRCD) Cheap From Peers?

Brocade Communications Systems, Inc. (BRCD) knifed -0.32 percent lower and now trades for $12.29. BRCD comes in with a P/S ratio of 2.17 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (13.12) and its peers (89.99). Also, it has an estimated price-earnings (P/E) multiple of 17.48 and a trailing 12-month price-earnings (P/E) multiple of 166.08. During the last 52 weeks, the price has been as high as $12.72 and as low as $8.64. Brocade Communications Systems, Inc. (NASDAQ:BRCD) earnings have risen with a quarterly rate of 1.8% over the last 5 years. Shares of BRCD have sank -3.23% in the past three monthswhile the S&P 500 has dropped -7.6% in that time.

Brocade Communications Systems, Inc. (Price Objective: $12.75)

Brocade Communications Systems, Inc. (NASDAQ:BRCD) has a market cap of $5.08 billion and over the last 12 months, BRCD has risen by 36.1%. The average 1-year price target for (BRCD) reveals an average price target of $12.75 per share. That’s a potential 3.74 gain from where (NASDAQ:BRCD) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $12.5. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $13.

Analyst Thoughts About Brocade Communications Systems, Inc. (NASDAQ:BRCD)

The consensus recommendation — averaging the work of 6 analysts — of 3 for Brocade Communications Systems, Inc. (BRCD) points to moderate case. Of the analysts surveyed by Reuters that track Brocade Communications Systems, Inc. 6 of them rate its stock a hold. The other 0 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 0 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NASDAQ:BRCD) or, if they already own its stock, sell it.